Therapeutic anticoagulation is indicated for a variety of circumstances and conditions in
several fields of medicine to prevent or treat venous and arterial thromboembolism …

Recent advances in our understanding of the contribution of thrombin generation to arterial
thrombosis and the role of platelets in venous thrombosis have prompted new treatment …

The most commonly used anticoagulants produce therapeutic antithrombotic effects either
by inhibiting thrombin or factor Xa (FXa) or by lowering the plasma levels of the precursors of …

Thrombosis is a leading cause of death and disability worldwide, and anticoagulants are the
mainstay of its prevention and treatment. Starting with unfractionated heparin (UFH) and …

Compared with vitamin K antagonists, the direct oral anticoagulants (DOACs) are simpler to
administer and are associated with less intracranial bleeding. Nonetheless, even with the …

Factor XIa (FXIa) in the intrinsic pathway of the coagulation process has been proven to be
an effective and safe target for anticoagulant discovery with limited or no bleeding …

Abstract Factor XIa (FXIa) is a serine protease homodimer that belongs to the intrinsic
coagulation pathway. FXIa primarily catalyzes factor IX activation to factor IXa, which …

Despite the introduction of direct oral anticoagulants (DOACs), the search for more effective
and safer antithrombotic strategies continues. Better understanding of the pathogenesis of …

Introduction: Anticoagulants are the mainstay for prevention and/or treatment of thrombotic
disorders. Each clinically used anticoagulant is associated with significant adverse …

Although the non-vitamin antagonist oral anticoagulants produce less intracranial bleeding
than warfarin, serious bleeding still occurs. Therefore, the search for safer anticoagulants …